EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
3.4.22.29 | Abortion, Habitual |
34489969 |
Decreased USP2a Expression Inhibits Trophoblast Invasion and Associates With Recurrent Miscarriage. |
causal interaction unassigned |
3 0 |
3.4.22.29 | Adenocarcinoma |
22585994 |
MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. |
causal interaction diagnostic usage therapeutic application unassigned |
4 3 3 0 |
3.4.22.29 | Adenocarcinoma |
24071644 |
USP2a alters chemotherapeutic response by modulating redox. |
unassigned |
0 |
3.4.22.29 | Adenocarcinoma of Lung |
29490279 |
USP2a Supports Metastasis by Tuning TGF-? Signaling. |
causal interaction ongoing research therapeutic application unassigned |
4 2 4 0 |
3.4.22.29 | Breast Neoplasms |
19838211 |
MdmX is a substrate for the deubiquitinating enzyme USP2a. |
therapeutic application unassigned |
2 0 |
3.4.22.29 | Carcinoma |
19362044 |
Clinicopathological significance of ubiquitin-specific protease 2a (USP2a), fatty acid synthase (FASN), and ErbB2 expression in oral squamous cell carcinomas. |
causal interaction diagnostic usage ongoing research therapeutic application |
3 3 3 1 |
3.4.22.29 | Carcinoma, Embryonal |
19838211 |
MdmX is a substrate for the deubiquitinating enzyme USP2a. |
therapeutic application unassigned |
2 0 |
3.4.22.29 | Carcinoma, Hepatocellular |
33074477 |
Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A. |
therapeutic application unassigned |
1 0 |
3.4.22.29 | Cardiomyopathies |
10086389 |
Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. |
causal interaction unassigned |
1 0 |
3.4.22.29 | Cardiomyopathies |
11056105 |
Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy. |
causal interaction therapeutic application unassigned |
4 2 0 |